Protea Biosciences, Inc. and Mayoly-Spindler Announce Human Clinical Trial for New Biopharmaceutical
MORGANTOWN, W.Va., June 22, 2010 (GLOBE NEWSWIRE) -- Protea Biosciences, Inc., a leading developer of new technology for pharmaceutical research, announced today that the company, in partnership with Mayoly-Spindler, a European pharmaceutical company, has commenced a Phase I/IIA human clinical trial for a new recombinant Lipase.